Cardiovascular disease treatment sustained-release tablets and preparation method thereof
A sustained-release tablet and cardiovascular technology, which is applied in the field of sustained-release tablets for the treatment of cardiovascular diseases and its preparation, and can solve problems such as the difficulty in meeting the quality control standards for free salicylic acid in aspirin
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
Method used
Image
Examples
Embodiment 1
[0163] Embodiment 1: Aspirin dipyridamole sustained release tablet
[0164] Dipyridamole Sustained Release Tablets Isolation Layer Coated Tablet Core:
[0165]
[0166] Isolation coat:
[0167] Opadry 80W 620004Yellow 3kg
[0168] 20% ethanol solution 28kg
[0169] Aspirin mix granules:
[0170]
[0171] Protective Coating:
[0172] Opadry 295K 620010Yellow 8kg
[0173] 80% ethanol solution 126kg
[0174] Weigh dipyridamole, hypromellose K4M, and lactose according to the prescription amount, put them in a wet granulator in sequence, use 30% ethanol as a soft material, granulate with an 18-mesh sieve, and dry the material to LOD at a temperature not exceeding 45°C ≤2.0%, granulate with 10 mesh sieve; add stearic acid, mix evenly; use Φ=9.5mm shallow concave punch to compress tablet; Opadry 80W 620004Yellow isolation layer coating weight increase to 3%, as dipyridamole Sustained-release tablet core coated with an isolation layer; crush aspirin through a 30-mesh siev...
Embodiment 2
[0175] Embodiment 2: aspirin dipyridamole sustained release tablet
[0176] Dipyridamole Sustained Release Tablets Isolation Layer Coated Tablet Core:
[0177]
[0178] Isolation coat:
[0179] Opadry 80W 620004Yellow 2kg
[0180] 10% ethanol solution 20kg
[0181] Aspirin mix granules:
[0182]
[0183] Protective Coating:
[0184] Opadry 295K 620010Yellow 10kg
[0185] 95% ethanol solution 150kg
[0186]Weigh dipyridamole, hypromellose K4M, and lactose according to the prescription amount, place them in a wet granulator in turn, use 20% ethanol as a soft material, and granulate with a 30-mesh sieve. The temperature of the material does not exceed 50 ° C, and it is dried to LOD≤1.0%, granulate with 10 mesh sieve; add stearic acid, mix evenly; use Φ=9.5mm shallow concave punch to compress tablet; Opadry 80W 620004Yellow isolation layer coating weight increase to 2%, as dipyrid Mo Sustained Release Tablets isolation layer coating tablet core; crush aspirin through ...
Embodiment 3
[0187] Embodiment 3: aspirin dipyridamole sustained release tablet
[0188] Dipyridamole Sustained Release Tablets Isolation Layer Coated Tablet Core:
[0189]
[0190] Isolation coat:
[0191] Opadry 80W 620004Yellow 4kg
[0192] 30% ethanol solution 35kg
[0193] Aspirin mix granules:
[0194]
[0195] Protective Coating:
[0196] Opadry 295K 620010Yellow 6kg
[0197] 60% ethanol solution 100kg
[0198] Weigh dipyridamole, hypromellose K4M, and lactose according to the prescription amount, place them in a wet granulator in turn, use 40% ethanol as a soft material, and granulate with a 10-mesh sieve. The temperature of the material does not exceed 35 ° C, and it is dried to LOD≤3.0%, granulate with 20 mesh sieve; add stearic acid, mix evenly; use Φ=9.5mm shallow concave punch to compress tablet; Opadry 80W 620004Yellow isolation layer coating weight increase to 4%, as dipyrid Mo Sustained Release Tablets are coated with an isolation layer; aspirin is crushed thro...
PUM
Login to View More Abstract
Description
Claims
Application Information
Login to View More 